Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTH1R | Q03431 | 10/20 | 0.71 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL850218 | 0.91 | PTH1R (0.85) | PTH1RSCN9AMMP2MMP3SLC6A9 | |
| SCHEMBL13552148 | 0.85 | PTH1R (0.56) | PTH1RSCN9AMMP2MMP3SLC6A9 | |
| SCHEMBL849795 | 0.85 | PTH1R (0.54) | PTH1RSCN9AMMP2MMP3 | |
| SCHEMBL13555104 | 0.85 | PTH1R (0.55) | PTH1RSCN9AMMP2MMP3SLC6A9 | |
| SCHEMBL847213 | 0.84 | PTH1R (0.57) | PTH1RSCN9AMMP2MMP3SLC6A9 | |
| SCHEMBL848837 | 0.83 | PTH1R (0.57) | PTH1RSCN9ACCNT1CDK9 | |
| SCHEMBL848836 | 0.83 | PTH1R (0.57) | PTH1RSCN9ACCNT1CDK9 | |
| SCHEMBL16087609 | 0.83 | PTH1R (0.53) | PTH1RSCN9AMMP2MMP3SLC6A9 | |
| SCHEMBL849454 | 0.83 | PTH1R (0.53) | PTH1RSCN9AMMP2MMP3SLC6A9 | |
| SCHEMBL849891 | 0.82 | PTH1R (0.54) | PTH1RSCN9AMMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2433940-B9 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2015-10-28 | — | — | EP | claimed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | claimed |
| EP-2433940-B1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-09-24 | — | — | EP | claimed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | claimed |
| EP-2433940-A1 | SPIROIMIDAZOLONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-03-28 | — | — | EP | claimed |
| US-20220162208-A1 | HYDANTOIN DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-05-26 | — | — | US | disclosed |
| US-20210024524-A1 | HYDANTOIN DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-01-28 | — | — | US | disclosed |
| US-9993462-B2 | Hydantoin derivative-containing pharmaceutical composition | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-06-12 | — | — | US | disclosed |
| US-9993462-B2 | Hydantoin derivative-containing pharmaceutical composition | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-06-12 | — | — | US | disclosed |
| US-20170112812-A1 | HYDANTOIN DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-04-27 | — | — | US | disclosed |
| US-20170112812-A1 | HYDANTOIN DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-04-27 | — | — | US | disclosed |
| US-20160326175-A1 | HYDANTOIN DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-10 | — | — | US | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-20150274727-A1 | HYDANTOIN DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-01 | — | — | US | disclosed |
| US-20150274727-A1 | HYDANTOIN DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-01 | — | — | US | disclosed |
| EP-2433940-B1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| WO-2010126030-A1 | SPIROIMIDAZOLONE DERIVATIVE | 中外製薬株式会社 (JP) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | PTH1R 1869/4885SCN9A 553/4885MMP2 2725/4885 |
| US-20170112812-A1 | HYDANTOIN DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-3, H1-0 | PTH1R 376/4885SCN9A 2206/4885MMP2 495/4885 |
| US-20210024524-A1 | HYDANTOIN DERIVATIVE | HRH4, HRH3, H1-3 | PTH1R 2316/4885SCN9A 1454/4885MMP2 2480/4885 |
| US-20160326175-A1 | HYDANTOIN DERIVATIVE | SLC10A1, UGT1A1, CYP2D6 | PTH1R 4241/4885SCN9A 735/4885MMP2 1744/4885 |
| US-20150274727-A1 | HYDANTOIN DERIVATIVE | HRH4, HRH3, H1-3 | PTH1R 2316/4885SCN9A 1454/4885MMP2 2480/4885 |
| US-20220162208-A1 | HYDANTOIN DERIVATIVE | HRH4, HRH3, H1-3 | PTH1R 2316/4885SCN9A 1454/4885MMP2 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.